Core Viewpoint - Northeast Pharmaceutical (000597) announced that its subsidiary, Shenyang First Pharmaceutical Co., Ltd., received the drug registration certificate from the National Medical Products Administration for Levetiracetam Extended-Release Tablets, which is approved for use in patients aged 12 and above for adjunctive treatment of partial seizures in epilepsy [1] Summary by Category - **Product Approval** - The drug name is Levetiracetam Extended-Release Tablets, with the approval number Guoyao Zhunzi H20253711, valid until March 24, 2030 [1] - The medication is specifically indicated for patients aged 12 years and older who experience partial seizures as part of their epilepsy treatment [1]